Adagio Medical Advances VT Treatment with FDA PMA Submission and Positive Trial Data — Adagio Medical Holdings, Inc.

Event summary

Adagio Medical submitted a Premarket Approval (PMA) application to the FDA for its vCLAS Ventricular Ablation System, supported by the FULCRUM-VT trial data.
The FULCRUM-VT trial showed an 84% freedom from ICD shock and a 78% discontinuation or reduced dose of antiarrhythmic drugs at six months.
Adagio treated its first patient with the next-generation vCLAS Ultra catheter under FDA Expanded Access authorization.
Net loss for Q2 2026 was $6.7 million, up from $3.9 million in Q2 2025, driven by higher R&D and SG&A expenses.

The big picture

Adagio Medical is positioning itself as a key player in the treatment of ventricular arrhythmias with its proprietary ULTA technology. The submission of the PMA application marks a critical milestone, potentially expanding its market reach beyond Europe. The company's focus on both ischemic and non-ischemic cardiomyopathy patients underscores its commitment to addressing unmet needs in cardiac arrhythmia treatment.

What we're watching

Regulatory Approval: Whether the FDA will approve the vCLAS Ventricular Ablation System based on the FULCRUM-VT trial data.
Commercial Execution: How Adagio will navigate the pause in commercial activity in Europe while advancing its next-generation products.
Financial Sustainability: The pace at which Adagio can reduce its net loss as it scales its operations and secures regulatory approvals.